Correlation between IL6, IFγ, and clinico-pathological characteristics_
| IL6 | IFγ | |||||
|---|---|---|---|---|---|---|
| Median ± SD | r | P | Median ± SD | r | P | |
| Total | 56.20 ± 28.715 | 76.37 ± 41.54 | ||||
| Age | 58.36 ± 23.45 | 0.012 | 0.934 | 81.63 ± 37.36 | −0.043 | 0.769 |
| Tumor size | ||||||
| T1 | 11.10 ± 20.33 | 0.614 | 0.001 | 80.43 ± 44.03 | 0.07 | 0.631 |
| T2 | 22.40 ± 27.73 | 76.25 ± 36.63 | ||||
| T3 | 33.20 ± 34.06 | 66.63 ± 59.47 | ||||
| T4 | 65.80 ± 36.12 | 60.13 ± 37.41 | ||||
| Nodal status | ||||||
| N1 | 20.90 ± 28.89 | 0.933 | >0.0001 | 118.15 ± 31.07 | −0.45 | 0.01 |
| N2 | 39.14 ± 39.36 | 86.72 ± 67.74 | ||||
| N3 | 67.31 ± 28.89 | 76.37 ± 44.46 | ||||
| Metastasis | ||||||
| M1 | 56.65 ± 33.00 | 0.852 | 0.008 | 52.50 ± 24.40 | −0.172 | 0.238 |
| M0 | 29.4 ± 28.11 | 81.20 ± 42.66 | ||||
| Stage | ||||||
| I | 4.60 ± 30.12 | 0.761 | >0.0001 | 86.00 ± 48.57 | −0.38 | 0.02 |
| II | 14.20 ± 28.32 | 79.72 ± 37.25 | ||||
| III | 34.15 ± 30.42 | 53.08 ± 45.21 | ||||
| IV | 68.16 ± 18.10 | 52.25 ± 26.18 | ||||
| Hormonal status | ||||||
| Estrogen receptor | ||||||
| Positive | 56.75 ± 28.36 | 0.245 | 0.09 | 77.68 ± 41.97 | 0.01 | 0.945 |
| Negative | 16.70 ± 4.56 | 76.18 ± 0 | ||||
| Progesterone receptor | ||||||
| Positive | 59.36 ± 28.50 | 0.95 | 0.517 | 81.09 ± 42.41 | −0.029 | 0.842 |
| Negative | 40.25 ± 44.62 | 76.30 ± 6.94 | ||||
| Her 2 neu | ||||||
| Positive | 58.75 ± 22.00 | 0.324 | 0.07 | 76.09 ± 37.63 | −0.05 | 0.733 |
| Negative | 47.20 ± 29.25 | 77.68 ± 41.17 | ||||
| Ki67 | ||||||
| >20% | 62.2 ± 29.84 | −0.113 | 0.45 | 76.00 ± 41.70 | −0.157 | 0.293 |
| <20% | 49.92 ± 27.59 | 87.60 ± 42.54 | ||||
| Subtype | ||||||
| Luminal A | 62.20 ± 27.54 | 0.19 | 0.06 | 87.60 ± 45.92 | −0.099 | 0.498 |
| Luminal B | 55.20 ± 30.49 | 76.37 ± 42.29 | ||||
| Her 2 neu enriched | 58.75 ± 25.22 | 76.09 ± 25.58 | ||||
| Body mass index | ||||||
| Normal | 38.95 ± 38.73 | 0.39 | 0.05 | 69.21 ± 60.60 | −0.044 | 0.766 |
| Overweight | 55.20 ± 14.29 | 96.88 ± 24.62 | ||||
| Obese | 69.05 ± 29.46 | 76.27 ± 42.17 | ||||
Patient characteristics_
| Number (78) | % | P value | |
|---|---|---|---|
| Median age | 54 (29–78) | ||
| Tumor size | |||
| T1 | 11 | 14.1% | < 0.00001 |
| T2 | 49 | 62.8% | |
| T3 | 13 | 16.7% | |
| T4 | 5 | 6.4% | |
| Nodal status | |||
| N0 | 27 | 34.6% | < 0.00001 |
| N1 | 30 | 38.5% | |
| N2 | 7 | 9% | |
| N3 | 14 | 17.9% | |
| Metastasis | |||
| M1 | 8 | 10.26% | < 0.00001 |
| M0 | 70 | 89.74% | |
| Stage | |||
| I | 12 | 15.5% | < 0.00001 |
| II | 37 | 47.4% | |
| III | 26 | 33.3% | |
| IV | 3 | 3.8% | |
| Hormonal status | |||
| Estrogen receptor (ER) | |||
| Positive | 74 | 94.9% | < 0.00001 |
| Negative | 4 | 5.1% | |
| Progesterone receptor (PR) | |||
| Positive | 75 | 96.1% | < 0.00001 |
| Negative | 3 | 3.9% | |
| Her 2 neu | |||
| Positive | 13 | 16.7% | < 0.00001 |
| Negative | 65 | 83.3% | |
| Ki67 | |||
| >20% | 48 | 61.5% | 0.00024 |
| <20% | 30 | 38.5% | |
| Subtype | |||
| Lumina A | 23 | 29.5% | < 0.00001 |
| Luminal B | 42 | 53.8% | |
| Her 2 neu enriched | 13 | 16.7% | |
| Body mass index | |||
| Normal | 6 | 7.7% | < 0.00001 |
| Overweight | 8 | 10.2% | |
| Obese | 64 | 82.1% | |
| Chemotherapy | |||
| Yes | 33 | 67.3% | < 0.00001 |
| No | 16 | 32.7% | |
| Radiotherapy | |||
| Yes | 70 | 89.8% | < 0.00001 |
| No | 8 | 10.2% |